EndGenitor Technologies

EndGenitor Technologies is a biotechnology company focused on developing regenerative cell therapies to treat vascular and ischemic diseases. Founded by Dr. Mervin Yoder, a pioneer in vascular biology, the company utilizes a proprietary platform to isolate and expand Endothelial Colony Forming Cells (ECFCs), which are highly potent progenitor cells capable of forming new, functional blood vessels. Their therapeutic approach aims to restore blood flow in patients suffering from conditions like critical limb ischemia and peripheral artery disease. Additionally, the company is exploring the application of these cells in accelerating the healing of chronic, non-healing wounds such as diabetic foot ulcers. By leveraging the natural angiogenic potential of ECFCs, EndGenitor seeks to provide a transformative alternative to traditional surgical interventions.